C Fogarty
Overview
Explore the profile of C Fogarty including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
178
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Alkhars N, Zeng Y, Alomeir N, Al Jallad N, Wu T, Aboelmagd S, et al.
J Dent Res
. 2021 May;
101(1):54-62.
PMID: 34018817
Despite the cariogenic role of suggested from recent studies, oral acquisition in children at high risk for early childhood caries (ECC) and its association with cariogenic bacteria remain unclear. Although...
2.
Donohue J, Hanania N, Fogarty C, Campbell S, Rinehart M, Denis-Mize K
Ther Adv Respir Dis
. 2009 Jan;
2(4):199-208.
PMID: 19124372
Unlabelled: Formoterol fumarate is a long-acting beta2-agonist that is an effective bronchodilator for the maintenance management of patients with chronic obstructive pulmonary disease. The safety profile of the newly developed...
3.
van Noord J, Cornelissen P, Aumann J, Platz J, Mueller A, Fogarty C
Respir Med
. 2008 Nov;
103(1):22-9.
PMID: 19022642
Background: Tiotropium, a once daily inhaled anticholinergic delivered via HandiHaler, provides bronchodilation for >24h and improves patient-centred outcomes. The Respimat Soft Mist Inhaler (SMI), a novel, propellant-free inhaler, has been...
4.
Carbon C, van Rensburg D, Hagberg L, Fogarty C, Tellier G, Rangaraju M, et al.
Respir Med
. 2005 Dec;
100(4):577-85.
PMID: 16376537
This retrospective analysis was performed to determine the clinical and bacteriologic efficacy of the ketolide antibacterial telithromycin in patients with community-acquired pneumonia (CAP) with pneumococcal bacteremia. Patients 13 years old...
5.
Fogarty C, Torres A, Choudhri S, Haverstock D, Herrington J, Ambler J
Int J Clin Pract
. 2005 Oct;
59(11):1253-9.
PMID: 16236076
This pooled analysis of six prospective, multicentre trials aimed to determine the efficacy of moxifloxacin in community-acquired pneumonia (CAP) due to penicillin-, macrolide- and multidrug-resistant Streptococcus pneumoniae (MDRSP). At a...
6.
van Rensburg D, Fogarty C, Kohno S, Dunbar L, Rangaraju M, Nusrat R
Chemotherapy
. 2005 Jun;
51(4):186-92.
PMID: 15980629
Background: The efficacy of oral telithromycin was assessed in patients with community-acquired pneumonia (CAP) caused by Streptococcus pneumoniae with reduced susceptibility to penicillin and/or erythromycin. Methods: Patients with CAP who...
7.
Fogarty C, Zervos M, Tellier G, Aubier M, Rangaraju M, Nusrat R
Int J Clin Pract
. 2005 Apr;
59(3):296-305.
PMID: 15857326
Pooled data from three randomized, double-blind, multi- centre studies evaluated the efficacy and tolerability of telithromycin 800 mg once daily for 5 days vs. standard comparators (10-day amoxicillin-clavulanate 500/125 mg...
8.
Sethi S, Fogarty C, Fulambarker A
Respir Med
. 2004 Aug;
98(8):697-707.
PMID: 15303633
Objective: To demonstrate that 5 days of treatment with a new fluoroquinolone, gemifloxacin, is at least as effective as 7 days of treatment with levofloxacin in adult patients with acute...
9.
Hagberg L, Carbon C, van Rensburg D, Fogarty C, Dunbar L, Pullman J
Respir Med
. 2003 Jun;
97(6):625-33.
PMID: 12814146
The efficacy of telithromycin has been assessed in six Phase III studies involving adults with mild to moderate community-acquired pneumonia (CAP) with a degree of severity compatible with oral therapy....
10.
Gotfried M, DeAbate C, Fogarty C, Mathew C, Sokol W
Clin Ther
. 2001 Feb;
23(1):97-107.
PMID: 11219483
Background: The ideal duration of antibiotic therapy for acute exacerbation of chronic bronchitis (AECB) remains controversial. Objective: This study compared short-course, 5-day gatifloxacin treatment with standard 10-day clarithromycin treatment in...